Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers
- PMID: 35543241
- DOI: 10.1080/08982104.2022.2069809
Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers
Abstract
Phospholipids have a high degree of biocompatibility and are deemed ideal pharmaceutical excipients in the development of lipid-based drug delivery systems, because of their unique features (permeation, solubility enhancer, emulsion stabilizer, micelle forming agent, and the key excipients in solid dispersions) they can be used in a variety of pharmaceutical drug delivery systems, such as liposomes, phytosomes, solid lipid nanoparticles, etc. The primary usage of phospholipids in a colloidal pharmaceutical formulation is to enhance the drug's bioavailability with low aqueous solubility [i.e. Biopharmaceutical Classification System (BCS) Class II drugs], Membrane penetration (i.e. BCS Class III drugs), drug uptake and release enhancement or modification, protection of sensitive active pharmaceutical ingredients (APIs) from gastrointestinal degradation, a decrease of gastrointestinal adverse effects, and even masking of the bitter taste of orally delivered drugs are other uses. Phospholipid-based colloidal drug products can be tailored to address a wide variety of product requirements, including administration methods, cost, product stability, toxicity, and efficacy. Such formulations that are also a cost-effective method for developing medications for topical, oral, pulmonary, or parenteral administration. The originality of this review work is that we comprehensively evaluated the unique properties and special aspects of phospholipids and summarized how the individual phospholipids can be utilized in various types of lipid-based drug delivery systems, as well as listing newly marketed lipid-based products, patents, and continuing clinical trials of phospholipid-based therapeutic products. This review would be helpful for researchers responsible for formulation development and research into novel colloidal phospholipid-based drug delivery systems.
Keywords: Phospholipid based drug delivery; glycerophospholipids; lecithin; lipid excipients safety profile; lipid research; phasphatidylcholine; sphingophospholipids.
Similar articles
-
Phospholipids and lipid-based formulations in oral drug delivery.Pharm Res. 2010 Aug;27(8):1469-86. doi: 10.1007/s11095-010-0130-x. Epub 2010 Apr 22. Pharm Res. 2010. PMID: 20411409 Review.
-
Tailoring the multi-functional properties of phospholipids for simple to complex self-assemblies.J Control Release. 2022 Sep;349:460-474. doi: 10.1016/j.jconrel.2022.07.014. Epub 2022 Jul 18. J Control Release. 2022. PMID: 35841998 Review.
-
Comparison of the in vitro cytotoxicity among phospholipid-based parenteral drug delivery systems: Emulsions, liposomes and aqueous lecithin dispersions (WLDs).Eur J Pharm Sci. 2019 Jan 15;127:92-101. doi: 10.1016/j.ejps.2018.10.018. Epub 2018 Oct 17. Eur J Pharm Sci. 2019. PMID: 30342174
-
Review - An update on the use of oral phospholipid excipients.Eur J Pharm Sci. 2017 Oct 15;108:1-12. doi: 10.1016/j.ejps.2017.07.008. Epub 2017 Jul 12. Eur J Pharm Sci. 2017. PMID: 28711714 Review.
-
The role of phospholipids in drug delivery formulations - Recent advances presented at the Researcher's Day 2023 Conference of the Phospholipid Research Center Heidelberg.Eur J Pharm Biopharm. 2024 Apr;197:114215. doi: 10.1016/j.ejpb.2024.114215. Epub 2024 Feb 11. Eur J Pharm Biopharm. 2024. PMID: 38350530
Cited by
-
Mitochondria-Targeted Delivery Strategy of Dual-Loaded Liposomes for Alzheimer's Disease Therapy.Int J Mol Sci. 2023 Jun 22;24(13):10494. doi: 10.3390/ijms241310494. Int J Mol Sci. 2023. PMID: 37445673 Free PMC article.
-
Oxymatrine and astragaloside IV co-loaded liposomes: Scale-up purposes and their enhancement of anti-PD-1 efficacy against breast cancer.Mater Today Bio. 2025 Mar 4;32:101634. doi: 10.1016/j.mtbio.2025.101634. eCollection 2025 Jun. Mater Today Bio. 2025. PMID: 40177381 Free PMC article.
-
Phospholipid-Drug Conjugates in Cancer Therapy: Emerging Paradigms and Future Directions.AAPS PharmSciTech. 2025 Jul 14;26(6):190. doi: 10.1208/s12249-025-03175-8. AAPS PharmSciTech. 2025. PMID: 40659903 Review.
-
PEGylation in Pharmaceutical Development: Current Status and Emerging Trends in Macromolecular and Immunotherapeutic Drugs.Cureus. 2024 Aug 12;16(8):e66669. doi: 10.7759/cureus.66669. eCollection 2024 Aug. Cureus. 2024. PMID: 39262507 Free PMC article. Review.
-
Phospholipid Complex Formulation Technology for Improved Drug Delivery in Oncological Settings: a Comprehensive Review.AAPS PharmSciTech. 2024 Apr 25;25(5):91. doi: 10.1208/s12249-024-02813-x. AAPS PharmSciTech. 2024. PMID: 38664316 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources